See more : DCX Systems Limited (DCXINDIA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Quince Therapeutics, Inc. (QNCX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quince Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vaxxinity, Inc. (VAXX) Income Statement Analysis – Financial Results
- Piovan S.p.A. (PVN.MI) Income Statement Analysis – Financial Results
- Signal Hill Acquisition Corp. (SGHLU) Income Statement Analysis – Financial Results
- Chitradurga Spintex Limited (CHITRTX.BO) Income Statement Analysis – Financial Results
- Applied Minerals, Inc. (AMNL) Income Statement Analysis – Financial Results
Quince Therapeutics, Inc. (QNCX)
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| Gross Profit | -322.00K | -175.00K | -344.00K | -332.00K | -188.00K | -51.00K | -45.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M | 9.10M |
| General & Administrative | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.70M | 26.01M | 29.52M | 17.59M | 8.95M | 2.03M | 1.27M |
| Other Expenses | 7.48M | -997.00K | -247.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Cost & Expenses | 34.62M | 51.19M | 90.32M | 78.89M | 39.17M | 12.12M | 10.37M |
| Interest Income | 3.48M | 1.07M | 620.00K | 2.04M | 2.19M | 806.00K | 0.00 |
| Interest Expense | 0.00 | 568.00K | 0.00 | 0.00 | 0.00 | 957.00K | 1.64M |
| Depreciation & Amortization | 322.00K | 175.00K | 344.00K | 332.00K | 188.00K | 51.00K | 45.00K |
| EBITDA | -31.26M | -52.02M | -89.97M | -78.56M | -38.98M | -12.07M | -10.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M | -10.37M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.04M | 71.00K | 373.00K | 2.04M | 2.19M | -357.00K | -1.87M |
| Income Before Tax | -31.58M | -51.94M | -89.95M | -76.85M | -36.98M | -12.48M | -12.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -197.00K | -284.00K | -620.00K | 2.17M | -188.00K | 357.00K | 1.87M |
| Net Income | -31.39M | -51.66M | -89.33M | -76.85M | -36.79M | -12.48M | -12.24M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| EPS Diluted | -0.84 | -1.54 | -3.01 | -2.63 | -1.93 | -0.58 | -0.57 |
| Weighted Avg Shares Out | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
| Weighted Avg Shares Out (Dil) | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 21.55M | 21.55M |
The Anatomy of Penny Stocks: Understanding What Drives Value
Here's how to understand what components drive value with penny stocks The post The Anatomy of Penny Stocks: Understanding What Drives Value appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Identify Potentially Profitable Penny Stocks to Buy
Use these tips for finding penny stocks to buy The post How to Identify Potentially Profitable Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Quince Therapeutics (NASDAQ:QNCX) Stock Up 53% Today?
Quince Therapeutics (NASDAQ: QNCX ) stock is rocketing higher on Friday after completing an asset sale to Lighthouse Pharmaceuticals. This sale covers the company's legacy small molecule protease inhibitor portfolio.
Quince Therapeutics to Present at Upcoming Scientific Meetings
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including...
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on...
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for...
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock...
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports